Castleview Partners’s Exelixis EXEL Stock Holding History

Castleview Partners’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-22	Closed	-$352	–	681
2022 Q4	$352	Buy	+22	New	+$359	﹤0.01%	595

Other funds holding EXEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Castleview Partners's EXEL Position: Q1 2023 in Review

Castleview Partners sold out of Exelixis (EXEL) in Q1 2023, closing a stake of 22 shares — an estimated $352 sold.

Castleview Partners first reported a position in EXEL in Q4 2022 and held it in 1 quarter. The position peaked at $352 in Q4 2022. 363 funds tracked by Wall St. Rank hold EXEL as of Q1 2023.

Castleview Partners reported no remaining Exelixis position as of Q1 2023 after selling out during the quarter.
Castleview Partners sold 22 Exelixis shares in Q1 2023, an estimated $352.
Castleview Partners first reported a position in Exelixis in Q4 2022 and held it in 1 quarter.
Castleview Partners's Exelixis position peaked at $352 in Q4 2022.
363 funds tracked by Wall St. Rank held Exelixis as of Q1 2023.

Based on Castleview Partners's 13F filing for Q1 2023, filed 16 May 2023.